Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

This study is testing a CAR-T cell therapy — a type of immune cell treatment — for people with aggressive lymphoma or acute lymphoblastic leukemia (ALL) that has relapsed (come back) or is not responding to standard treatments. The therapy uses genetically modified versions of your own immune cells that are trained to seek out and destroy cancer cells. **You may be eligible if...** - You have relapsed or treatment-resistant aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) - You are between 2 and 70 years old (children require guardian consent) - You are in reasonably good physical condition (able to care for yourself) - Your organs (heart, lungs, liver, kidneys) are functioning adequately **You may NOT be eligible if...** - You have active untreated brain involvement by cancer - You have a serious autoimmune disease - You have had prior CAR-T cell therapy - You are pregnant or breastfeeding - You have severe uncontrolled infections Talk to your doctor to see if this trial is right for you.